| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443582 | European Journal of Cancer | 2014 | 7 Pages |
Abstract
The addition of cediranib 20Â mg daily to carboplatin/paclitaxel chemotherapy increased RR and toxicity, but not survival.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
S.A. Laurie, B.J. Solomon, L. Seymour, P.M. Ellis, G.D. Goss, F.A. Shepherd, M.J. Boyer, A.M. Arnold, P. Clingan, F. Laberge, D. Fenton, V. Hirsh, M. Zukin, M.R. Stockler, C.W. Lee, E.X. Chen, A. Montenegro, K. Ding, P.A. Bradbury,